More is not better: PARP dose can be safely reduced for people with ovarian cancer
Full article:

Maintenance therapy with a PARP inhibitor is now the standard of care for many people with advanced or recurrent ovarian cancer. However, PARP inhibitors may have significant side effects. This study shows that reducing the dose of a PARP inhibitor does not affect survival. (Posted 11/8/22)

Este artículo está disponible en español.

Expert Guidelines

The following NCCN recommendations are for maintenance therapy for women with ovarian cancer who have had a complete or partial response to first-line therapy:

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following are studies looking at PARP inhibitors and similar agents for treating people with ovarian cancer.  


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.